Merck’s MRK strong oncology sales growth is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

While the fianlimab arm showed a numerical improvement in progression-free survival, the difference was not statistically ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

FDA Alerts on Risks From Merck’s Keytruda in Multiple Myeloma Following Halted Trials The US Food and Drug Administration (FDA) on Thursday released an alert and summary of findings from two halted ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

The gap between US drug prices and those abroad is not a market outcome — it is the result of deliberate political and ...

The US Food and Drug Administration (FDA) announced Tuesday that it has limited the use of Roche’s Tecentriq (atezolizumab) and Merck’s Keytruda (pembrolizumab) for patients with locally advanced or ...